Humacyte does not pay a dividend yield to its shareholders. As an emerging, clinical-stage biotechnology enterprise focused entirely on funding ongoing research and development, clinical trials, and early commercialization scaling, the company retains all available capital to support business operations rather than distributing cash returns to equity holders.